Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T21:39:16.161Z.
Calculation as of: 2026-10-06T21:39:16.161Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 49ccfc7bc81d1e6c211e00ba0f17dd71ad394db50a55f8cf6fe3d6b4e4d88636
PEG RATIO
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zenas BioPharma, Inc. (ZBIO) | $1.70B | N/A | N/A | N/A | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.71B | N/A | 6.61 | 5.90 | 4.86 |
| Personalis, Inc. (PSNL)vs › | $1.71B | N/A | N/A | N/A | N/A |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.73B | N/A | N/A | N/A | N/A |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.74B | N/A | N/A | N/A | N/A |
| Xeris Biopharma Holdings, Inc. (XERS)vs › | $1.74B | N/A | N/A | N/A | N/A |
| Absci Corporation (ABSI)vs › | $1.74B | N/A | N/A | N/A | N/A |
| Novocure Ltd (NVCR)vs › | $1.74B | N/A | N/A | N/A | N/A |
| Surgery Partners, Inc. (SGRY)vs › | $1.75B | N/A | N/A | N/A | N/A |
| Generate Biomedicines, Inc. (GENB)vs › | $1.77B | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
